Clinical Trial Search

Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants

Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants

Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…

Primary: Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 — 8 Percentage of participants

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants

Primary: Objective Tumor Response (Complete or Partial) — 0 percentage of participants

Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…

Primary: Objective Overall Response Rate — 2; 0 participants

Primary: Objective Tumor Response — 11.8 percentage

Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months

Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants

Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients

Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 0 Participants

Primary: 3-year Overall Survival — 17 partipants

Primary: Participant Responses — 2; 8; 4; 6 participants

Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants

Primary: Objective Response Rates (ORR) — 74.4 percentage of participants

Primary: Objective Response Rate (ORR) — 26 Percentage of participants

Primary: Progression Free Survival — 3.7 months

Primary: Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by…

Primary: Number of Participants Alive at Time of Last Follow-up. — 376; 385; 271; 280 Participants

Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)

Primary: Anti-tumor Activity as Measured by Surviving Progression-free — 59 percentage of participants

Primary: Tumor Response — 0; 1; 12; 11 participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Overall Disease Control Rate — 17 percentage of participants

Primary: Progression-free Survival Greater Than 6 Months — 31; 21 participants